Eleanor Lisbon, MD, MPH
President & Principal Consultant, LisBio Research, LLC
Global Drug Development Leader | Sickle Cell Disease Expertise | Phase 1–3
Strategist
Dr. Eleanor Lisbon is a physician and pharmaceutical executive with over 18 years in clinical drug development: Phase 1-Phase 3, multiple therapeutic areas. Dr. Lisbon has held previous leadership roles at small and midsize biotech companies as well as large CRO and pharma companies. Prior to her industry work, she was an Associate Professor of Family Medicine at the University of Kansas Medical Center (KUMC), USA for 10 years.
Dr. Lisbon earned her undergraduate and medical degrees from Howard University, Washington, DC., and earned her Master’s in Public Health (MPH) degree from the University of Kansas, Department of Preventive Medicine. Additionally, she holds a certificate in Executive Education from Harvard Kennedy School, Boston, Massachusetts, USA.
Dr. Lisbon is a former Executive Medical Director at Pfizer with deep expertise in first-in-human (FIH), Phase 1 clinical development and safety review, specializing in small molecules and hemoglobinopathies, including sickle cell disease. Dr. Lisbon led the global clinical programs for Osivelotor at Global Blood Therapeutics (GBT) and Pfizer, including program strategy, regulatory engagement, and global key opinion leader engagement. Prior to GBT, she served as Vice President of Clinical Development at Imara, directing a multinational Phase 2b program and early phase expansion for IMR-687.
Dr. Lisbon has proficiency in clinical pharmacology, exposure–response, modeling and simulation, dose escalation, with a proven track record of accelerating earlystage pipelines and advancing therapies from IND through pivotal trials.
Dr. Lisbon has authored/co-authored published manuscripts in peer reviewed journals and has several accepted abstracts/presentations as co-author at the American Society of Hematology (ASH) in 2020-2023, 2025; the European Hematologic Association (EHA) 2022, 2024 and 2025 and the American Society of Clinical Pharmacologists 2023 and 2025.
In June of 2025, Dr. Lisbon founded LisBio, LLC – a boutique consultancy specializing in strategic design and oversight of rare disease trials. She continues to have a keen Interest and growing expertise in accelerated drug discovery.
